Delivery Order SPE2DR25D2013-SPE2DR26F5RDB
- Not listed
- The Defense Logistics Agency awarded a $6,973.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on January 16, 2026, with completion targeted for February 9, 2026. This is a non-set-aside, competitively awarded contract executed at the company's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp operates as a subsidiary of parent company Cencora, Inc. (formerly known as AmerisourceBergen), a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $3,082.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with a completion date of August 21, 2025. This non-competitive award was issued to the company's corporate office located in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly for military and...
- The Defense Logistics Agency awarded a $3,486.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on January 7, 2026, with completion scheduled for January 29, 2026. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as the primary vehicle for supplying pharmaceutical products and medical...
- The Defense Logistics Agency awarded a $6,973.34 delivery order to AmerisourceBergen Drug Corp (parent company: Cencora, Inc.) on January 23, 2026, for the supply of Benlysta 200 mg/ml auto-injector units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of February 13, 2026. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under the...
- The Defense Logistics Agency awarded a $6,497.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on December 22, 2025, with a completion date of January 14, 2026. This non-set-aside competitive award represents a single delivery order for the lupus treatment medication to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a $3,082.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injectors, with an ultimate completion date of November 10, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $13,946.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector pharmaceutical product. The contract was competitively awarded without set-aside designation and is scheduled for completion by February 13, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $24,636.28 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of October 14, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was...
- The Defense Logistics Agency awarded a delivery order valued at $13,946.68 to AmerisourceBergen Drug Corp on January 28, 2026, for the supply of Benlysta 200 mg/ml auto-injector medication. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of February 19, 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a subsidiary of Cencora, Inc., a major...
- AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $6,973.34 on January 7, 2026, by the Defense Logistics Agency for the supply of Benlysta 200 mg/mL auto-injectors. The award is non-competitive and structured as a firm fixed-price delivery order, with performance completion scheduled for January 29, 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and primary...
- SPE2DR25D2013Indefinite Delivery Contract
- SPE2DR25D2013-SPE2DR26F5RDBDelivery Order
The Defense Logistics Agency awarded a $3,486.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 30, 2026, for the supply of Benlysta 200 mg/ml auto-injectors, with completion scheduled for February 23, 2026. This is a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, operates as a subsidiary of Cencora, Inc. (formerly known as AmerisourceBergen) and serves as a critical pharmaceutical distributor supporting federal medical procurement needs across military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Benlysta, a biologic treatment for systemic lupus erythematosus, supports the Defense Health Agency and broader military healthcare programs requiring specialty rheumatologic medications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 1/29/26 |